This program fosters research and instruction in the areas of trauma and hemorrhage to translate the experimental studies to the bedside using novel treatment modalities so that complications and mortality rates in such trauma patients can be decreased.

Along with the Center for Phase I Studies, the pharmacokinetic and pharmacodynamic studies have been contracted to a GLP facility to obtain safety and toxicity information for filing an IND application and obtaining approval from the FDA for conducting the Phase I studies of EE-3-SO₄. More specifically, the contract titled “Surviving Blood Loss: First In Human Studies To Assess Safety And Physiological Effects Of Synthetic Ethinyl Estradiol-3-Sulfate (EE-3-SO₄) In Healthy Subjects Both Euvolemic And Following 10-20% Inatrogenic Blood Loss” has been awarded since September 2015 to the tune of $10 million to complete the preclinical studies so that Phase I studies of EE-3-SO₄ can then be performed.